​

Celldex Therapeutics (CLDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CLDX Stock Forecast

Celldex Therapeutics (CLDX) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $45.00, with a high of $45.00 and a low of $45.00. This represents a 35.18% increase from the last price of $33.29.

$25 $30 $35 $40 $45 $50 High: $45 Avg: $45 Low: $45 Last Closed Price: $33.29

CLDX Stock Rating

Celldex Therapeutics stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (78.95%), 4 Hold (21.05%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 4 15 Strong Sell Sell Hold Buy Strong Buy

CLDX Price Target Upside V Benchmarks

TypeNameUpside
StockCelldex Therapeutics35.18%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts114
Avg Price Target$45.00$45.00$28.75
Last Closing Price$33.29$33.29$33.29
Upside/Downside35.18%35.18%-13.64%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 261131-116
Mar, 261122-116
Feb, 261122-116
Jan, 261122-116
Dec, 251122-116
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 20, 2026Barclays$45.00$34.5530.25%35.18%
Dec 17, 2025Barclays$24.00$26.68-10.04%-27.91%
Nov 11, 2025Barclays$21.00$22.67-7.37%-36.92%
Oct 13, 2025Barclays$25.00$26.77-6.61%-24.90%
Mar 20, 2025Morgan Stanley$46.00$19.88131.39%38.18%
Oct 29, 2024Joseph PantginisH.C. Wainwright$80.00$27.12194.99%140.31%
Sep 25, 2024Derek ArchilaWells Fargo$44.00$36.0222.15%32.17%
Jun 17, 2024Alex ThompsonStifel Nicolaus$58.00$34.9166.14%74.23%
Nov 10, 2023Derek ArchilaWells Fargo$27.00$25.784.73%-18.89%
Nov 11, 2022Guggenheim$63.00$39.8957.93%89.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 20, 2026BarclaysUnderweightOverweightupgrade
Mar 02, 2026Goldman SachsNeutralNeutralhold
Oct 13, 2025BarclaysUnderweightinitialise
Mar 20, 2025Morgan StanleyOverweightinitialise
Jan 08, 2025CitigroupBuyBuyhold
Oct 29, 2024H.C. WainwrightBuyBuyhold
Oct 28, 2024Cowen & Co.BuyBuyhold
Oct 28, 2024Wolfe ResearchBuyBuyhold
Oct 28, 2024GuggenheimBuyBuyhold
Oct 07, 2024CitigroupBuyinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.64$-2.40$-2.92$-2.45$-3.90---
Avg Forecast$-1.64$-2.38$-2.80$-2.45$-3.28$-3.79$-3.75$-1.07
High Forecast$-0.84$-1.61$-2.60$-2.35$-2.93$-2.85$-3.15$-0.61
Low Forecast$-2.97$-3.71$-2.95$-2.59$-3.55$-4.82$-4.28$-1.74
Surprise %-0.84%4.29%-18.90%---

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.65M$2.36M$6.88M$7.02M$1.54M---
Avg Forecast$5.34M$988.00K$4.11M$6.83M$4.00M$2.84M$51.13M$328.93M
High Forecast$8.67M$1.41M$4.95M$8.32M$5.95M$2.85M$76.03M$489.11M
Low Forecast$3.34M$742.71K$3.22M$5.67M$2.68M$2.82M$34.22M$220.10M
Surprise %-12.90%138.56%67.57%2.80%-61.42%---

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-70.51M$-112.33M$-141.43M$-157.86M$-258.76M---
Avg Forecast$-79.46M$-86.68M$-141.43M$-119.81M$-157.14M$-185.74M$-180.08M$-51.60M
High Forecast$-40.83M$-69.35M$-113.14M$-114.06M$-142.17M$-138.09M$-152.63M$-29.41M
Low Forecast$-143.95M$-104.02M$-169.71M$-125.56M$-172.12M$-233.39M$-207.53M$-84.26M
Surprise %-11.26%29.58%-31.76%64.66%---

CLDX Forecast FAQ

Is Celldex Therapeutics stock a buy?

Celldex Therapeutics stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Celldex Therapeutics is a favorable investment for most analysts.

What is Celldex Therapeutics's price target?

Celldex Therapeutics's price target, set by 19 Wall Street analysts, averages $45 over the next 12 months. The price target range spans from $45 at the low end to $45 at the high end, suggesting a potential 35.18% change from the previous closing price of $33.29.

How does Celldex Therapeutics stock forecast compare to its benchmarks?

Celldex Therapeutics's stock forecast shows a 35.18% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Celldex Therapeutics over the past three months?

  • April 2026: 6.25% Strong Buy, 81.25% Buy, 6.25% Hold, 0% Sell, 6.25% Strong Sell.
  • March 2026: 6.25% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.
  • February 2026: 6.25% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 6.25% Strong Sell.

What is Celldex Therapeutics’s EPS forecast?

Celldex Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.79, marking a -2.82% decrease from the reported $-3.9 in 2025. Estimates for the following years are $-3.75 in 2027, and $-1.07 in 2028.

What is Celldex Therapeutics’s revenue forecast?

Celldex Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $2.84M, reflecting a 83.62% increase from the reported $1.54M in 2025. The forecast for 2027 is $51.13M, and $328.92M for 2028.

What is Celldex Therapeutics’s net income forecast?

Celldex Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-186M, representing a -28.22% decrease from the reported $-259M in 2025. Projections indicate $-180M in 2027, and $-51.598M in 2028.